Why the study?
Does anakinra reduce recurrences, emergency department admissions, and hospitalisations in patients with corticosteroid-dependent and colchicine-resistant recurrent pericarditis?
Does anakinra reduce recurrences, emergency department admissions, and hospitalisations in patients with corticosteroid-dependent and colchicine-resistant recurrent pericarditis?
Anakinra is an efficacious and safe treatment option for reducing recurrences and healthcare utilization in patients with refractory recurrent pericarditis.
Answers are grounded in this paper and cite their sources.
May support anakinra in refractory recurrent pericarditis; leaves open need for randomized confirmation.
In patients with recurrent pericarditis, anakinra appears efficacious and safe in reducing recurrences, emergency department admissions and hospitalisations.
No takes yet. Share an insight, caveat, or question.
Imazio et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: